Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NR56
UPID:
MBNL1_HUMAN
Alternative names:
Triplet-expansion RNA-binding protein
Alternative UPACC:
Q9NR56; E9PBW7; O43311; O43797; Q86UV8; Q86UV9; Q96P92; Q96RE3
Background:
Muscleblind-like protein 1, also known as Triplet-expansion RNA-binding protein, plays a pivotal role in pre-mRNA alternative splicing regulation. It can act as both an activator and repressor of splicing on specific targets, influencing key processes in muscle and cardiac function. This protein's ability to bind to specific RNA sequences and structures, including expanded CUG repeat RNA, underscores its importance in cellular mechanisms.
Therapeutic significance:
Muscleblind-like protein 1 is implicated in the pathogenesis of Dystrophia myotonica 1 and Fuchs endothelial corneal dystrophy, 3. Its interaction with pathogenic RNAs highlights a critical role in these diseases, suggesting that targeting MBNL1 could offer novel therapeutic avenues for treating conditions characterized by aberrant splicing.